Jnpmedi

JNPMEDI Inc. is a South Korean life sciences research, development and commercialization (RDC) company serving pharmaceutical, biotech and medical device customers. Its core product is Maven Clinical Cloud, a proprietary end-to-end eClinical suite for clinical trial operations and data management. The suite spans Maven CDMS (clinical data management), Maven eCOA, Maven Docs, Maven eTMF, Maven Safety, Maven CDISC, Maven VDR (virtual data room) and the Maven DCT Suite, which includes eConsent, Rscreening, Rvisit, RTSM and Auditor+ modules. Other listed Maven Clinical Cloud components include Maven Coder, Maven EDC, Maven Builder, Maven Auditor and Maven Trigger.

Around the software, JNPMEDI sells professional services covering the product lifecycle: a digital-based full-scope CRO offering (medical writing, project management, clinical operations, data management, biostatistics, pharmacovigilance); CDCO services for digital medical devices and digital therapeutics spanning proof-of-concept and product development, exploratory and confirmatory trials, commercialization support for FDA and MFDS approvals, and post-market surveillance; investment and licensing services including due diligence, algorithm-based value assessment, deal sourcing and liaison/project management; and AWS managed services. The company frames its positioning as moving from "clinical science to data science" (Vision 1.0) toward a broader life science enablement platform (Vision 2.0).

Founding story

JNPMEDI was established in 2020 with the stated aim of enhancing Korea's medical infrastructure by applying blockchain and cloud computing through an advanced medical data platform.

Business model

JNPMEDI combines software with services: it licenses its Maven Clinical Cloud modules and, per a third-party profile, sells subscription tiers (Maven Standard, Maven Professional, Maven Extensive), while also delivering fee-based CRO, CDCO, regulatory, investment/licensing consulting and AWS managed services built around those solutions.

Software subscriptions across tiered plans (Maven Standard, Maven Professional, Maven Extensive) together with contracted professional services engagements in clinical research, development, commercialization and cloud management.

Traction

Company-reported achievements include more than 240 clinical trial sites, over 4,000 solution usages, more than 30,000 subject enrollments and over 4 million data records.

Latest developments

Reported developments include selection for the government-backed Global TIPS program with approximately KRW 5 billion in state support over four years for AI-based Clinical OS development, selection for the 2026 Unicorn Bridge program following DIPS, an MOU with Samsung Medical Center on medical device usability evaluation, and, per a third-party profile, an August 2025 venture financing from new investors Naver and TBT Partners.